Two randomised trials in 280 vaccine-naive healthy adults: a 25-valent pneumococcal conjugate vaccine (PCV25) had adverse event profiles similar to PCV20; at the highest dose it gave ≥2-fold IgG and OPA rises for all 25 serotypes (except OPA for 35B).
RCTn = 280
Langley et al. Safety and immunogenicity of a 25-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive healthy adults: Results from 2 randomised, controlled clinical trials